Sign In
Buy CCCC
$4.12
-0.0300 (-0.723%)
At Close: Jun 22, 2026
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
10:41am, Thursday, 18'th Jun 2026
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
10:58am, Tuesday, 02'nd Jun 2026
I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through pha
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
01:02pm, Monday, 01'st Jun 2026
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
C4 Therapeutics to Participate in Upcoming Conferences
07:00am, Wednesday, 20'th May 2026
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) scie
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 18'th May 2026
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, t
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
10:41am, Friday, 15'th May 2026
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
09:11am, Tuesday, 12'th May 2026
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.37 per share a year ago.
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
07:00am, Tuesday, 12'th May 2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) scie
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
09:34am, Thursday, 09'th Apr 2026
C4 Therapeutics said on Thursday it has entered into a deal focused on research and development of a type of cancer drug with Swiss drugmaker Roche that could be worth more than $1 billion.
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Up 58.8% in March
04:26am, Saturday, 28'th Mar 2026
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910 sh
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 27'th Mar 2026
Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy
